teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions

vida: extract claims from 2026-q1-psychopharmacology-glp1-psychiatric-review #10253

Closed
vida wants to merge 0 commits from extract/2026-q1-psychopharmacology-glp1-psychiatric-review-6fcf into main
pull from: extract/2026-q1-psychopharmacology-glp1-psychiatric-review-6fcf
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-05-06 04:33:27 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-q1-psychopharmacology-glp1-psychiatric-review.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 3
  • Decisions: 0
  • Facts: 4

0 claims, 3 enrichments. This source provides critical regulatory context for existing KB claims about GLP-1 psychiatric effects. The key insight is that the FDA's suicidality warning removal was based on definitive evidence (91 RCTs, 107K patients) showing no signal, and that the original warning was a policy artifact from non-GLP-1 drugs. This context explains why the regulatory asymmetry (eating disorder signal ignored, suicidality formally reviewed) resolved the way it did. The Psychopharmacology Institute's coverage signals professional psychiatric education is incorporating GLP-1 as psychiatric pharmacology, but no new screening protocols were provided. All insights enrich existing claims rather than introducing novel mechanisms.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-q1-psychopharmacology-glp1-psychiatric-review.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 4 0 claims, 3 enrichments. This source provides critical regulatory context for existing KB claims about GLP-1 psychiatric effects. The key insight is that the FDA's suicidality warning removal was based on definitive evidence (91 RCTs, 107K patients) showing no signal, and that the original warning was a policy artifact from non-GLP-1 drugs. This context explains why the regulatory asymmetry (eating disorder signal ignored, suicidality formally reviewed) resolved the way it did. The Psychopharmacology Institute's coverage signals professional psychiatric education is incorporating GLP-1 as psychiatric pharmacology, but no new screening protocols were provided. All insights enrich existing claims rather than introducing novel mechanisms. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-06 04:33:28 +00:00
vida: extract claims from 2026-q1-psychopharmacology-glp1-psychiatric-review
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
07eddb984d 
- Source: inbox/queue/2026-q1-psychopharmacology-glp1-psychiatric-review.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-06 04:33:34 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-05-06 04:33 UTC

<!-- TIER0-VALIDATION:07eddb984d94d152d35f0c48e2712f8eed2e3089 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-05-06 04:33 UTC*
vida commented 2026-05-06 04:33:55 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims are factually correct, as the new evidence provided supports the assertions made in both glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md and semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence is distinct and adds unique information to each claim.
  3. Confidence calibration — The confidence levels are appropriate for the evidence provided, as the new information reinforces the existing claims without overstating their certainty.
  4. Wiki links — The wiki links in glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md have been updated to include new related claims, and while some may be broken if those claims are not yet merged, this does not affect the verdict.
1. **Factual accuracy** — The claims are factually correct, as the new evidence provided supports the assertions made in both `glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md` and `semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md`. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence is distinct and adds unique information to each claim. 3. **Confidence calibration** — The confidence levels are appropriate for the evidence provided, as the new information reinforces the existing claims without overstating their certainty. 4. **Wiki links** — The wiki links in `glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md` have been updated to include new related claims, and while some may be broken if those claims are not yet merged, this does not affect the verdict. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-06 04:34:08 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — All three files have valid frontmatter for their types: the two claim files contain type, domain, confidence, source, created, and description fields; the inbox source file follows source schema conventions.

  2. Duplicate/redundancy — The enrichment to semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md duplicates evidence already present in the claim body (the 42% reduction finding from the Swedish study is already the core claim), while the enrichment to glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md adds genuinely new evidence about psychiatric education incorporating GLP-1s into CME platforms.

  3. Confidence — Both claims are rated "high" confidence; the first claim's confidence is justified by the within-individual design eliminating confounding, and the second claim's confidence is appropriate given the structural analysis of prescriber competency gaps supported by professional recommendations.

  4. Wiki links — The related links array in the first file includes a self-referential link "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring" which appears to be the file linking to itself, and "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible" which may not exist yet, but as instructed these broken/circular links do not affect the verdict.

  5. Source quality — The Psychopharmacology Institute is a credible CME platform for practicing psychiatrists, making it an appropriate source for claims about psychiatric education and clinical practice patterns in the GLP-1 domain.

  6. Specificity — Both claims are falsifiable: someone could disagree by demonstrating that primary care providers do have adequate psychiatric monitoring protocols, or by showing that the Swedish study's 42% reduction was confounded by unmeasured variables.

The enrichment to semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md restates the 42% reduction already in the claim body without adding substantively new information, though the note about observational limitations adds minor value. The enrichment to the competency gap claim genuinely extends the evidence base.

## Criterion-by-Criterion Review 1. **Schema** — All three files have valid frontmatter for their types: the two claim files contain type, domain, confidence, source, created, and description fields; the inbox source file follows source schema conventions. 2. **Duplicate/redundancy** — The enrichment to `semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md` duplicates evidence already present in the claim body (the 42% reduction finding from the Swedish study is already the core claim), while the enrichment to `glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md` adds genuinely new evidence about psychiatric education incorporating GLP-1s into CME platforms. 3. **Confidence** — Both claims are rated "high" confidence; the first claim's confidence is justified by the within-individual design eliminating confounding, and the second claim's confidence is appropriate given the structural analysis of prescriber competency gaps supported by professional recommendations. 4. **Wiki links** — The related links array in the first file includes a self-referential link `"glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring"` which appears to be the file linking to itself, and `"glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible"` which may not exist yet, but as instructed these broken/circular links do not affect the verdict. 5. **Source quality** — The Psychopharmacology Institute is a credible CME platform for practicing psychiatrists, making it an appropriate source for claims about psychiatric education and clinical practice patterns in the GLP-1 domain. 6. **Specificity** — Both claims are falsifiable: someone could disagree by demonstrating that primary care providers do have adequate psychiatric monitoring protocols, or by showing that the Swedish study's 42% reduction was confounded by unmeasured variables. <!-- ISSUES: near_duplicate --> The enrichment to `semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design.md` restates the 42% reduction already in the claim body without adding substantively new information, though the note about observational limitations adds minor value. The enrichment to the competency gap claim genuinely extends the evidence base. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-06 04:34:08 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-06 04:34:08 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-06 04:34:56 +00:00
Owner
Copy link

Merged locally.
Merge SHA: f259748f7094c84fc07dc0ac87d74540e8340e00
Branch: extract/2026-q1-psychopharmacology-glp1-psychiatric-review-6fcf

Merged locally. Merge SHA: `f259748f7094c84fc07dc0ac87d74540e8340e00` Branch: `extract/2026-q1-psychopharmacology-glp1-psychiatric-review-6fcf`
leo closed this pull request 2026-05-06 04:34:57 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10253
No description provided.
Delete branch "extract/2026-q1-psychopharmacology-glp1-psychiatric-review-6fcf"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?